Biocon Inaugurates First US Manufacturing Facility in Cranbury

On Sep 12, 2025

Biocon Limited, an innovation-led global biopharmaceutical company out of India, announced the inauguration of its first US manufacturing facility in Cranbury by its wholly owned subsidiary, Biocon Generics Inc.

Biocon acquired the Cranbury-based Oral Solid Dosage facility from Eywa Pharma Inc. in 2023 and has since invested more than $30 million to establish a state-of-the-art plant with an annual production capacity of 2 billion tablets. A few products have already been commercialized from the site, with several more in the pipeline. This investment helps Biocon diversify its manufacturing base, strengthen its supply chain and accelerate the expansion of its global footprint.

The pharmaceutical company also has six manufacturing sites in India, and a major insulin manufacturing site in Malaysia.

The Cranbury facility represents a strategic advancement for the company’s US operations, enabling faster access to essential therapies, enhanced supply reliability and a stronger connection with partners and healthcare providers, ultimately benefitting patients across the US.

“Our decision [to expand in the US] is based on the company’s strategy which is to create access. I think COVID taught us a lot about how you need to get manufacturing closer to the patient, especially if you’re manufacturing life-saving drugs,” Abhijit Zutshi, chief commercial officer of Biocon Limited told New Jersey Business Magazine.

Gov. Phil Murphy, served as the guest of honour at the inauguration and was joined by Biocon’s Chairperson, Kiran Mazumdar-Shaw, along with other dignitaries, customers, partners, and industry leaders.

“Biocon’s first US FDA approved formulations facility in New Jersey marks a new chapter in our journey of global expansion. More than a milestone, it is a reaffirmation of our purpose to serve patients wherever they are,” Mazumdar-Shaw said.

She added that Governor Murphy’s presence at the inauguration highlights the importance of Biocon’s role in fostering innovation, creating job opportunities, and strengthening the US healthcare ecosystem. “This facility reflects the company’s long-term commitment to deeper engagement with healthcare providers, innovators, and communities to build a healthier and equitable future,” she said.

Biocon has approximately 60 employees at the new facility (40 employees joined from Eywa, while Biocon hired the rest), and plans to grow to about 80 to 85 people managing the facility over the next few months.

Siddharth Mittal, chief executive officer and managing director, Biocon Ltd, commented, “We were deeply honoured to have Governor Phil Murphy and our Chairperson, Kiran Mazumdar-Shaw, join us in marking this milestone of the Biocon Group’s first manufacturing facility in the US. This strategic investment brings us closer to patients, healthcare providers, and partners in this important market. The proximity allows us to deliver our vertically integrated, high-quality medicines more efficiently to patients across the United States and other markets, ensuring supply chain resilience and enabling us to advance our mission of expanding access to affordable therapies worldwide.”

“We are incredibly grateful that Biocon has decided to open its first US manufacturing facility in the Garden State,” said Murphy. “For years, Biocon has provided high-quality medicines and treatments to millions of patients across the globe. This state-of-the-art facility marks a significant moment in Biocon’s global expansion and reinforces New Jersey’s reputation as the medicine chest to the world.”

To access more business news, visit NJB News Now.

Related Articles: